Cargando…

Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study

Evidence has shown that multidisciplinary tumor board conferences (MTBCs) improve patient management for various cancer types. However, few retrospective studies have investigated MTBC efficacy for patients with gynecologic cancers. Here, we prospectively aimed to evaluate how MTBCs influence patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Banghyun, Kim, Kidong, Choi, Jin Young, Suh, Dong Hoon, No, Jae Hong, Lee, Ho-Young, Eom, Keun-Yong, Kim, Haeryoung, Hwang, Sung Il, Lee, Hak Jong, Kim, Yong Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728725/
https://www.ncbi.nlm.nih.gov/pubmed/29310324
http://dx.doi.org/10.1097/MD.0000000000008089
_version_ 1783286059630592000
author Lee, Banghyun
Kim, Kidong
Choi, Jin Young
Suh, Dong Hoon
No, Jae Hong
Lee, Ho-Young
Eom, Keun-Yong
Kim, Haeryoung
Hwang, Sung Il
Lee, Hak Jong
Kim, Yong Beom
author_facet Lee, Banghyun
Kim, Kidong
Choi, Jin Young
Suh, Dong Hoon
No, Jae Hong
Lee, Ho-Young
Eom, Keun-Yong
Kim, Haeryoung
Hwang, Sung Il
Lee, Hak Jong
Kim, Yong Beom
author_sort Lee, Banghyun
collection PubMed
description Evidence has shown that multidisciplinary tumor board conferences (MTBCs) improve patient management for various cancer types. However, few retrospective studies have investigated MTBC efficacy for patients with gynecologic cancers. Here, we prospectively aimed to evaluate how MTBCs influence patient management in gynecologic oncology. This prospective study included 85 consecutive cases that were presented at gynecologic oncology MTBCs in our tertiary university hospital between January 2015 and April 2016. The primary endpoint was treatment plan change rate, which included both major and minor changes. Major changes were defined as exchange, addition, or subtraction of treatment modality. Minor changes included all other, such as intramodality changes or treatment time changes. The secondary endpoints were the change rates of diagnosis, diagnostic work-up, and radiological and pathological findings. The treatment plan change rate, irrespective of changes in diagnostic work-up, was 27.1%, which included 10.6% major and 16.5% minor changes. Among the treatment plan changes, changes in the treatment plan change rate alone were noted in 16.5% of cases, and changes in diagnosis and radiological findings occurred in 7.1% and 3.5% of cases, respectively. Diagnosis and radiological findings, irrespective of changes in diagnostic work-up, were also changed in 9.4% and 10.6% of cases, respectively. However, there were no changes in pathological findings. Moreover, there was a change of diagnostic method for further work-up in 23.5% of cases. The implementation rate of MTBC-determined treatment changes was 91.8%. Gynecologic oncology MTBCs resulted in considerable changes in treatment plans. Diagnosis, diagnostic work-up, and radiological findings were influenced by MTBCs. The data emphasize the importance of adopting a multidisciplinary team approach for gynecologic cancer management.
format Online
Article
Text
id pubmed-5728725
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57287252017-12-20 Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study Lee, Banghyun Kim, Kidong Choi, Jin Young Suh, Dong Hoon No, Jae Hong Lee, Ho-Young Eom, Keun-Yong Kim, Haeryoung Hwang, Sung Il Lee, Hak Jong Kim, Yong Beom Medicine (Baltimore) 5600 Evidence has shown that multidisciplinary tumor board conferences (MTBCs) improve patient management for various cancer types. However, few retrospective studies have investigated MTBC efficacy for patients with gynecologic cancers. Here, we prospectively aimed to evaluate how MTBCs influence patient management in gynecologic oncology. This prospective study included 85 consecutive cases that were presented at gynecologic oncology MTBCs in our tertiary university hospital between January 2015 and April 2016. The primary endpoint was treatment plan change rate, which included both major and minor changes. Major changes were defined as exchange, addition, or subtraction of treatment modality. Minor changes included all other, such as intramodality changes or treatment time changes. The secondary endpoints were the change rates of diagnosis, diagnostic work-up, and radiological and pathological findings. The treatment plan change rate, irrespective of changes in diagnostic work-up, was 27.1%, which included 10.6% major and 16.5% minor changes. Among the treatment plan changes, changes in the treatment plan change rate alone were noted in 16.5% of cases, and changes in diagnosis and radiological findings occurred in 7.1% and 3.5% of cases, respectively. Diagnosis and radiological findings, irrespective of changes in diagnostic work-up, were also changed in 9.4% and 10.6% of cases, respectively. However, there were no changes in pathological findings. Moreover, there was a change of diagnostic method for further work-up in 23.5% of cases. The implementation rate of MTBC-determined treatment changes was 91.8%. Gynecologic oncology MTBCs resulted in considerable changes in treatment plans. Diagnosis, diagnostic work-up, and radiological findings were influenced by MTBCs. The data emphasize the importance of adopting a multidisciplinary team approach for gynecologic cancer management. Wolters Kluwer Health 2017-12-01 /pmc/articles/PMC5728725/ /pubmed/29310324 http://dx.doi.org/10.1097/MD.0000000000008089 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5600
Lee, Banghyun
Kim, Kidong
Choi, Jin Young
Suh, Dong Hoon
No, Jae Hong
Lee, Ho-Young
Eom, Keun-Yong
Kim, Haeryoung
Hwang, Sung Il
Lee, Hak Jong
Kim, Yong Beom
Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study
title Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study
title_full Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study
title_fullStr Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study
title_full_unstemmed Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study
title_short Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study
title_sort efficacy of the multidisciplinary tumor board conference in gynecologic oncology: a prospective study
topic 5600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728725/
https://www.ncbi.nlm.nih.gov/pubmed/29310324
http://dx.doi.org/10.1097/MD.0000000000008089
work_keys_str_mv AT leebanghyun efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT kimkidong efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT choijinyoung efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT suhdonghoon efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT nojaehong efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT leehoyoung efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT eomkeunyong efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT kimhaeryoung efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT hwangsungil efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT leehakjong efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy
AT kimyongbeom efficacyofthemultidisciplinarytumorboardconferenceingynecologiconcologyaprospectivestudy